"Therapeutic Cancer Vaccines Market to 2019 - Pipeline Indicates Safer Treatments and Extended Patient Survival, Though High Prices May Limit Uptake" Is Now Available at Fast Market Research
GBI Research, the leading business intelligence provider, has released its latest research "Therapeutic Cancer Vaccines Market to 2019 - Pipeline Indicates Safer Treatments and Extended Patient Survival, though High Prices May Limit Uptake". There is currently only one marketed therapeutic cancer vaccine, Provenge, which is indicated for the treatment of castrate¬-resistant, asymptomatic metastatic prostate cancer which achieved global sales of approximately $215 million in 2011. Over the forecast period, numerous vaccines are anticipated to be approved over a range of...
View full press release